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We here report on the in vitro activity of toremifene to inhibit biofilm formation of different fungal and bacterial pathogens,
including Candida albicans, Candida glabrata, Candida dubliniensis, Candida krusei, Pseudomonas aeruginosa, Staphylococcus
aureus, and Staphylococcus epidermidis. We validated the in vivo efficacy of orally administered toremifene against C. albicans
and S. aureus biofilm formation in a rat subcutaneous catheter model. Combined, our results demonstrate the potential of
toremifene as a broad-spectrum oral antibiofilm compound.
Biofilm formation is a key process in many microbial infec-tions, including those of the oral cavity, the gastrointestinal
tract, the urinary tract, and various wound tissues. It is estimated
that 60% (Centers for Disease Control and Prevention) to 80%
(National Institutes of Health) of all microbial infections are bio-
film related. Additionally, numerous nosocomial biofilm infec-
tions arise from the increased use of implanted medical devices,
like intravascular catheters, which are a preferred niche formicro-
bial cell adherence (1). Such catheters frequently become colo-
nized with pathogenic Candida or Staphylococcus spp., especially
in intensive care units (2, 3). Biofilm-related infections are asso-
ciated with a high mortality rate, and therefore, the European
Society of Clinical Microbiology and Infectious Diseases (ESC-
MID) and the Infectious Diseases Society of America (IDSA) sug-
gest that infectedmedical devices be removedwhenpossible (4, 5).
However, removal of infected devices in less accessible locations,
such as orthopedic joints or heart valves, or in patients with a
reduced health condition might be impossible (2, 6, 7). Unfortu-
nately, in the case of fungal biofilm infections, most antifungal
drugs show only limited antibiofilm activity, with echinocandins
(e.g., caspofungin) and liposomal formulations of amphotericin B
being themost effective (2). Antifungal lock therapy to apply these
compounds can be successful but is restricted to devices with an
internal space. For treatment of other devices and for systemic
treatments, these compounds need to be administered intrave-
nously, as they are not absorbed after oral administration (5, 8).
To combat bacterial biofilm infection, themajor therapeutic strat-
egy is the use of antibiotics. However, the intrinsic and adaptive
resistance of bacterial biofilms to current antibiotics, as well as to
host immune clearance mechanisms, has led to a growing prob-
lem in health care settings. Staphylococcus aureus is amajor human
pathogen and is one of the most common pathogens in biofilm-
associated device infections (9, 10). Traditional antistaphylococ-
cal beta-lactam antibiotics like cephalexin are ineffective in clear-
ing methicillin-resistant S. aureus (MRSA) infections. Currently,
glycopeptide antibiotics (e.g., vancomycin) are often used in pa-
tients as a first-line treatment to target both methicillin-suscepti-
ble S. aureus (MSSA) andMRSA infections (11, 12). However, the
oral absorption of vancomycin is very low and, as a consequence,
this agentmust be administered intravenously to control systemic
infections (13). Alternatives, including the recently introduced
oxazolidinone linezolid and the cyclic lipopeptide daptomycin,
are available but the search for novel compounds to treat S. aureus
infections remains crucial (14).
In a previous study, we screened a repurposing library (i.e., a
library containing drugs known for their application in specific
medical domains) for compounds that can inhibit biofilm for-
mation of Candida albicans and/or can increase the activity of
well-known antifungal agents againstC. albicans biofilms. This led
to the identification of the FDA-approved anticancer drug
toremifene citrate (referred to hereafter as toremifene) as a potent
inhibitor of both C. albicans and Candida glabrata biofilm forma-
tion (15). The activity of toremifene against estrogen receptor-
positive (ER) breast cancer is based on its ability to bind the ER,
thereby blocking estrogen binding and leading to inhibition of
tumor growth (16). We already showed that the antibiofilm
activity of toremifene against C. albicans is partly mediated by
membrane permeabilization (15). Butts and colleagues further
demonstrated that the fungicidal activity of toremifene against
Cryptococcus neoformans is based on inhibition of calcineurin sig-
naling via calmodulin binding (17). The findings of these two
studies regarding the antifungal/antibiofilm mode of action of
toremifene are in line with the well documented antifungal mech-
anism of action of its close analogue tamoxifen, which is based on
membrane perturbation and interferencewith calciumhomeosta-
sis and calcineurin signaling (18–20). In the present study, we
report on the broad-spectrum antibiofilm activity of toremifene
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in vitro. In addition, we translated these results in vivo and show
activity of toremifene against C. albicans and S. aureus biofilm
formation in a rat subcutaneous cathetermodel (21), importantly,
via simple oral administration.
We used the BIC-2 value (minimal concentration of the com-
pound that inhibits biofilm formation 2-fold) to assess the antib-
iofilm activity of toremifene (TCI Europe, Zwijndrecht, Belgium)
for different fungal and bacterial species (Table 1). As a control
treatment, we included caspofungin. The in vitro antibiofilm ac-
tivities of toremifene and caspofungin against Candida spp. were
assayed in RPMI 1640 medium and quantified with the 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT) assay (22). Briefly, toremifene
(0.78 to 100 M, 0.5% dimethyl sulfoxide [DMSO] background)
was added during the adhesion (1 h at 37°C) and biofilm forma-
tion (24 h at 37°C) phases. Afterwards, biofilms were washed with
phosphate-buffered saline (PBS) and quantified with XTT as de-
scribed previously (15). XTT can be metabolized within 1 h by all
fungal species tested, in contrast to cell titer blue (CTB),whichwas
used in our initial study (15). We observed comparable in vitro
antibiofilm activities of toremifene againstC. albicans,C. glabrata,
Candida dubliniensis, and Candida krusei, albeit less potent than
those of caspofungin (Table 1). Subsequently, three clinical iso-
lates of C. albicans (2CA, 10CA, and 15CA) that form high-per-
sister biofilms (23) were assessed. Persister cells can survive high
doses of an antimicrobial agent and partly explain the recalci-
trance of chronic infectious diseases against antimicrobial
therapy (24, 25). Interestingly, C. albicans CA2 is susceptible to
toremifene, whereas C. albicans CA10 and CA15 are more resis-
tant (P  0.01 and P  0.00001, respectively, by unpaired two-
tailed Student’s t test). The activity of toremifene against plank-
tonic C. albicans cells was assessed according to the CLSI M27-A3
protocol (26). The MIC-2 (i.e., the MIC of the compound that
reduces growth by 2-fold relative to the results for the growth
control [0.5% DMSO]) for toremifene against C. albicans is
49.7  10.1 M (mean  standard error of the mean [SEM]),
which is comparable to its BIC-2 value against C. albicans (36 2
M) (Table 1). The latter observation indicates that toremifene
has no biofilm-specific activity and does not interfere specifically
with the biofilm formation process. The in vitro antibiofilm activ-
ities of toremifene against bacterial spp. were assayed using a Cal-
gary biofilm device (Nunc-Immuno TSP [transferable solid-
phase] replicator; VWR International). To this end, biofilms were
grown on the polystyrene pegs of the Calgary biofilm device for 24
h at 37°C in the presence of a range of concentrations of
toremifene (0 to 200M in a 0.5%DMSO background for Staph-
ylococcus spp. and a 1% DMSO background for Pseudomonas
aeruginosa). Next, the biofilms were disrupted and cells were col-
lected in recoverymediumusing sonication, after which the num-
ber of viable cells was assessed by plate counting (27). Our results
indicate that toremifene prevents in vitro biofilm formation of
Staphylococcus epidermidis and S. aureus, as illustrated by their low
BIC-2 values, whereas the activity of toremifene against P. aerugi-
nosa biofilm formation was approximately 10-fold less (Table 1).
In conclusion, we demonstrate in vitro activity of toremifene
against biofilm formation of different fungal and bacterial patho-
gens, including Candida and Staphylococcus spp. In view of the
inhibitory activity of toremifene against the fungus C. neoformans
and the Ebola virus reported previously (17, 28), our data further
highlight the broad-spectrum antibiofilm activity of toremifene.
Next, we translated these in vitro toremifene data against C.
albicans and S. aureus to a relevant in vivo rat subcutaneous cath-
etermodel (21). Animal experiments were approved by the ethical
committee of KU Leuven (project P125/2011) and animals were
maintained in accordance with the KU Leuven animal care guide-
lines. We used a low toremifene dose with reported anticancer
activity in rats (29–31), i.e., 3 mg/kg of body weight/day. Several
studies used considerably higher doses of toremifene in rodents,
ranging from 10 to 2,000mg/kg/day (32–35). However, due to the
limited solubility of toremifene in the vehicle solution (data not
shown), 3 mg/kg/day was the highest feasible dose that could be
tested in our experimental setup. The experimental setup of the in
vivo experiment was similar to those of previously reported stud-
ies (36, 37). Briefly, nine catheter fragments, infected with C. al-
bicans SC5314 (5  104 cells/ml) or S. aureus SH1000 (1  106
cells/ml) by static incubation in RPMI 1640 medium (90 min at
37°C), were implanted on the lower back of immunosuppressed
female Sprague-Dawley rats after washing twice with PBS (21).
The biofilm burdens on catheters after the adhesion period were
measured by obtaining CFU counts from three catheters, showing
1,022  204 adhered C. albicans and 38,000  4,041 adhered S.
aureus cells (mean  SEM) per catheter prior to implantation.
Starting at the day of implantation, 1 ml vehicle solution (28.8
g/liter polyethylene glycol 3000, 1.97 g/liter Tween 80, and 8.65
g/liter NaCl) with and without toremifene (0.6 mg/ml in vehicle,
or 3 mg/kg/day) was given by oral gavage daily for 7 days. Six (C.
albicans experiment) or 4 (S. aureus experiment) rats were treated
with toremifene, and 4 rats (both experiments) were treated with
the vehicle solution. Afterwards, rats were euthanized and biofilm
cells were dissociated from the removed catheters by sonication
and vortexing and quantified by counting CFU.
Oral administration of 3 mg/kg/day of toremifene resulted in
56% fewer C. albicans biofilm cells retrieved from the catheter
fragments than for the control treatment (5,158 881CFUversus
11,682 282 CFU for toremifene and the control treatment, re-
spectively; P 0.0004) (Fig. 1, left). Similarly, oral administration
of toremifene resulted in 57% fewer S. aureus biofilm cells re-
TABLE 1 Minimal BIC-2 values of toremifene and caspofungin against
fungal and bacterial pathogens
Organism
Reference or
source
Mean BIC-2 SEM
(M) ofa:
Tore CAS
Candida albicans SC5314 46 32 3 0.22 0.03
Candida albicans CA2 23 36 2 ND
Candida albicans CA10 23 85 8 ND
Candida albicans CA15 23 97 3 ND
Candida glabrata BG2 47 30 1 0.25 0.08
Candida dubliniensis NCPF 3949 48 23 4 0.22 0.05
Candida krusei IHEM 6104 BCCMb 26 3 0.35 0.11
Pseudomonas aeruginosa
UCBPP-PA14
49 46 7 NA
Staphylococcus epidermidis CH 50 3.9 0.3 NA
Staphylococcus aureus SH1000 51 3.5 0.7 NA
a BIC-2 values were determined by XTT for Candida spp. and by counting CFU for P.
aeruginosa and Staphylococcus spp. n 3 independent biological replicates. BIC-2,
biofilm inhibitory concentration that inhibits biofilm formation 2-fold; Tore,
toremifene; CAS, caspofungin; ND, not determined; NA, not applicable.
b BCCM, Belgian Coordinated Collections Of Microorganisms/IHEM (Brussels,
Belgium).
Toremifene Inhibits Microbial Biofilm Formation In Vivo
December 2014 Volume 58 Number 12 aac.asm.org 7607
 o
n
 N
ovem
ber 13, 2014 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
trieved from the catheters than for the control treatment
(2,441,701  638,290 CFU versus 5,707,540  468,832 CFU for
toremifene and the control treatment, respectively; P  0.0062)
(Fig. 1, right). These data indicate that toremifene (3 mg/kg/day)
is active in vivo againstC. albicans and S. aureus biofilm formation
upon oral administration. The efficacy of 3 mg/kg/day of the ref-
erence antifungal agent caspofungin against C. albicans biofilms
upon intravenous injectionwas previously demonstrated in a sim-
ilar in vivomodel (37). Even upon dosing rats at 50 mg/kg caspo-
fungin orally, no caspofungin could be detected in serum because
of low oral bioavailability (1%) (38). Hence, caspofungin can
only be applied by intravenous injection.
Note that theminimal dose of toremifene resulting in 50% death
(i.e., 50% lethal dose [LD50]) in rats is 3,000 mg/kg (toremifene
datasheet sc-253712 [http://datasheets.scbt.com/sc-253712.pdf];
Santa Cruz Biotechnology, Dallas, TX, USA), i.e., 1,000-fold
higher than the toremifene dose used in this study. The commonly
used dose of toremifene in humans for treating ER breast cancer
is 60 mg daily (16, 39). However, several clinical studies with
higher toremifene doses (200 and 240mg/day) in humans showed
no significant increase in toxic side effects compared to the stan-
dard dose of 60 mg toremifene daily (40–45). The latter studies
confirm that the toremifene dose used in this study (3mg/kg/day)
is achievable in humans. Toremifene (60 to 240 mg daily) is in
general well tolerated, and adverse side effects comprise mainly
hot flashes, sweating, nausea, vaginal discharge, dizziness, edema,
vomiting, and vaginal bleeding. In addition, an elevated risk of
thromboembolic events, endometrial cancer (higher for tamox-
ifen treatment), and a prolongation of theQT interval is noticed in
some cases when using ER modulators such as tamoxifen and
toremifene. Besides these adverse side effects, tamoxifen and
toremifene have positive effects on serum lipid levels (decreased
cholesterol) and bone mineral density (16, 44, 45).
In conclusion, toremifene is a broad-spectrum antibiofilm
compound that prevents C. albicans and S. aureus biofilm forma-
tion in vivo upon oral administration. The good oral bioavailabil-
ity of toremifenemakes toremifene a valuable systemic alternative
candidate for treating biofilm-associated fungal and bacterial de-
vice infections.
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